Insulin Resistance, Metabolic Syndrome X
Conditions
Brief summary
The aim of the study is to describe an immune activation profile of people at risk of insulin resistance based on a wide range of markers which will allow easy identification of patients at risk.
Interventions
OTHERBlood test
6ml blood sample taken
Sponsors
Centre Hospitalier Universitaire de Nīmes
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
55 Years to 69 Years
Healthy volunteers
Yes
Inclusion criteria
* The patient has been informed of the study, its objectives, constraints and the patient rights * The patient must have given their free and informed consent and signed the consent form * The patient is aged 55-69
Exclusion criteria
* The subject is participating in an interventional category 1 study * The patient has participated in another category 1 interventional study in the last 3 months * The patient is in a period of exclusion determined by a previous study * The patient is under safeguard of justice or state guardianship * The subject refuses to sign the consent * The subject does not understand the information
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| tissue plasminogen activator (tPa) level | Day 0 | ng/ml, enzyme-linked immunosorbent assays (ELISA) |
| Cluster of Differentiation 163 (CD163) level | Day 0 | ng/ml, enzyme-linked immunosorbent assays (ELISA) |
| soluble tumor necrosis factor-alpha receptor I (sTNFRI) level | Day 0 | ng/ml, enzyme-linked immunosorbent assays (ELISA) |
| soluble endothelial protein C Receptro (sEPCR) level | Day 0 | ng/ml, enzyme-linked immunosorbent assays (ELISA) |
| Cluster of Differentiation 4 (CD4+) T cell subpopulations | Day 0 | immunosenescence; number/mm3 |
| Cluster of Differentiation 8 (CD8+) T cell subpopulations | Day 0 | immunosenescence; number/mm3 |
| B cell subpopulations | Day 0 | flow cytometry |
| Natural killer (NK) cell subpopulations | Day 0 | immunosenescence; number/mm3 |
| sCD14 level | Day 0 | ng/ml, enzyme-linked immunosorbent assays (ELISA) |
| 16 ribosomal ribonucleic acid (rRNA) levels | Day 0 | polymerase chain reaction (PCR); copies/µl |
| lipopolysaccharide (LPS)-binding protein level | Day 0 | ELISA; µg/mL |
| Intestinal Fatty Acid Binding Protein level | Day 0 | ELISA; pg/mL |
| Total cholesterol | Day 0 | mM/L |
| High Density Lipoprotein | Day 0 | mM/L |
| Low Density Lipoprotein | Day 0 | mM/L |
| fasting glycemia | Day 0 | — |
| fasting insulinemia | Day 0 | mIU/L |
| γ-glutamyl transpeptidase level | Day 0 | — |
| glutamic pyruvic transaminase | Day 0 | — |
| hip circumference | Day 0 | cm |
| waist circumference | Day 0 | cm |
| minimal arterial tension | Day 0 | mmHg |
| maximal arterial tension | Day 0 | mmHg |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Link between immune activation profile and other features of metabolic syndrome | Day 0 | logistic regression of individual markers |
| Immune activation linked to the profile | Day 0 | logistic regression |
| Prevalence of insulin and metabolic syndrome | Day 0 | % subjects |
Countries
France
Outcome results
None listed